{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001045","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.452672+00:00","generated_at":"2026-05-24T03:21:29.545904+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"low","headline":"MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025","bullets":["Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.","Trial evaluates THIO sequenced with cemiplimab in advanced NSCLC patients after 2+ prior therapies.","Poster copy filed as Exhibit 99.1 and posted on company website; no specific numeric results in 8-K text.","Data disclosure under Regulation FD; forward-looking statements caution against undue reliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001045","json":"https://secwatch.observer/filing/0001641172-25-001045.json","markdown":"https://secwatch.observer/filing/0001641172-25-001045.md","text":"https://secwatch.observer/filing/0001641172-25-001045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/0001641172-25-001045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:21:29.545904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}